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medication and psychiatric comorbidity are largely ig-
nored in MMT treatment and research frameworks, al-
though they may serve to explain MMT’s limited 
treatment success. Emerging new opioid pharmacother-
apies require the fundamental review of the existing 
MMT paradigm as well as the application of rigorous and 
appropriate evaluation methods for future treatment. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 Illicit opioid dependence is a century-old phenome-
non, and despite its illegal context, the parameters and 
implications of this health problem are fairly well evi-
denced. There are an estimated 1.0–1.5 million illicit opi-
oid users in Western Europe, North America and Oceania 
combined.  [1–4] The huge mortality (direct, such as over-
dose; indirect, such as AIDS), morbidity and social cost 
impact of illicit opioid dependence, especially as they 
have increased over recent decades, have been extensive-
ly documented  [1–4] . 
 For the past three decades, the main treatment re-
sponse to the phenomenon of illicit opioid dependence 
has been opioid pharmacotherapy in the form of ‘metha-
done maintenance treatment’ (MMT). The treatment 
builds on pioneering research in North America in the 
1960s and the subsequently well publicized writings of 
Dole and Nyswander  [5, 6] . Since then, MMT availabil-
ity has continuously expanded, and the vast majority of 
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 Abstract 
 Background: Methadone maintenance treatment (MMT) 
has been the ‘gold standard’ pharmacotherapy treat-
ment for illicit opioid dependence for over 30 years. It 
has been widely evaluated, and is generally claimed to 
be ‘effective’.  Methods: The objective of this paper is to 
review the rationale of MMT as an intervention for a bio-
medical disorder with primary social objectives as well 
as the methodological quality and evidence of MMT out-
come research. Data sources included opioid depen-
dence treatment practice, review and outcome research 
literature (1965–2001) in the form of peer-reviewed arti-
cles, books, monographs and reports that are preemi-
nently cited and reviewed international studies on MMT. 
 Results/Data Synthesis: Rigorous and appropriate eval-
uation (i.e., RCTs, intent-to-treat, patient-centered) meth-
ods in MMT evaluations are rare. Evidence of MMT’s 
effectiveness on primary treatment objectives is mixed 
and appears to be largely partial and short-term. Positive 
outcomes may be the result of selection effects of com-
pliant patients and loss in proportion when more rigor-
ous standards of analysis are applied.  Conclusions: The 
quality of existing MMT research, and evidence for its 
general effectiveness are limited. Key concepts of self-
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the estimated 250,000–400,000 opioid-dependent indi-
viduals in treatment in Western Europe, North America 
and Oceania are receiving MMT  [7] . 
 Over the years, hundreds of evaluation studies on 
MMT have been conducted. At the beginning of the 
1990s, MMT was seen as ‘probably the most evaluated 
form of treatment in the ﬁ eld of drug abuse treatment’ 
 [8] . The predominant conclusion has been that MMT is 
an ‘effective treatment for heroin addiction’  [9] . A recent 
NIH research review, demanded barrier-free ‘access to 
MMT’ to ‘all who need it’  [10] . Evolving treatment sys-
tems (in emerging economies and the former socialist 
countries) are establishing MMT as the foundation for 
opioid dependence treatment. Thus, MMT has been es-
tablished as the ‘gold standard’ of opioid dependence 
treatment against which newly evolving alternative opi-
oid pharmacotherapy agents are automatically evaluated 
 [8, 11, 12] . 
 The basic idea underlying MMT is that opioid depen-
dence is a ‘medical disorder characterized by predictable 
signs and symptoms’ materializing at the genetic, mo-
lecular and neuronal levels  [10] . The crucial problem of 
opioid dependence is deﬁ ned as the subject’s ‘persistent 
or recurring craving’ for opioids, causing the negative 
consequences of illicit opioid use  [13] . MMT functions as 
a long-acting opioid substitute and ‘narcotic blockade’ 
preventing euphoria from additional heroin use; it there-
fore eliminates the negative consequences of opiate with-
drawal and allows for the effective ‘rehabilitation’ of the 
opioid-dependent individual  [5, 13, 14] . Over the years, 
general shortcomings of MMT have been recognized and 
debated, but none of them have managed to effectively 
challenge the predominant view of MMT as being cate-
gorically ‘effective’. Rather, the shortcomings were seen 
as being correlated to intrinsic or micro-details in treat-
ment provision, i.e., dosing, psychosocial treatment, in-
centives and rewards, allowing for ﬁ ne tuning towards 
‘optimal MMT’  [9, 15, 16] . Emerging new opioid phar-
macotherapy regimes have been cast as either equally ef-
fective alternatives to MMT (i.e., buprenorphine) or as a 
‘last resort’ treatment for a highly problematic, yet mar-
ginally small population of patients (i.e., heroin)  [7, 17, 
18] , therefore not challenging the existing hegemony of 
MMT in opioid dependence treatment. 
 The central purpose of this paper is to provide an eval-
uative review and analysis of current practices and out-
comes of opioid dependence treatment and research in 
light of the long history of MMT and the emerging diver-
sity of other opioid pharmacotherapy agents. 
 MMT’s Cross-Eyed Mission? Biomedical 
Treatment for Social Rehabilitation 
 In the context of the predominant biomedical models 
of illicit opioid dependence featuring patients suffering 
from ‘medical abnormalities and behavioral destabiliza-
tion’  [19] , a closer look at the primary expected objectives 
and outcomes of MMT reveals a peculiar slant. These 
objectives are characterized by two main features. First, 
MMT features main objectives of a social or a utilitarian 
nature. Consequently, the ‘success’ or ‘effectiveness’ of 
MMT is primarily operationalized by indicators that oc-
cur in or impact on larger, societal levels, rather than fo-
cusing on the individual patient’s subjective health status 
or well-being. For example, reductions in patients’ crim-
inal activity have traditionally been listed as a main ob-
jective of MMT as well as a primary outcome for many 
efﬁ cacy studies  [8–10, 20, 21] . Other usual endpoints in-
clude ‘social functioning’ or ‘social productivity’ (includ-
ing employment, care for family or children or even ‘mar-
riage’, etc.). While the patient’s health status has been an 
intervention goal and object of inquiry in many MMT 
evaluations, an increasing emphasis has been put instead 
on either public health perspectives (i.e., health problems 
or health risks incurred to others, e.g. through the spread 
of infectious disease) or the expenditure of health care 
resources  [8–10, 20, 21] . 
 In addition to criminality and social functioning, it is 
usually the elimination or reduction of the patient’s il-
licit (opioid and non-opioid) drug use that is used as a 
major endpoint in MMT  [8–10, 20, 21] . While this as-
pect, at ﬁ rst glance on ‘common sense’ grounds, may ap-
pear to be correlated to the patient’s direct well-being, 
explicit empirical evidence for this alleged linkage is pe-
culiarly absent from most MMT evaluations. It is not 
clear, however, what biological basis exists to assume that 
opioid ‘narcotic blockade’ (in the form of MMT) would 
alleviate a human agent’s craving for or even dependence 
on other drugs, such as marijuana or cocaine. At this end, 
MMT practice and assessment seems also starkly inﬂ u-
enced by abstract social (or moral) norms, rather than 
concrete and practical measures in favor of the individu-
al’s health or well-being.  
 This utilitarian perspective in objectives and assess-
ment of the supposed biomedical treatment of MMT is 
furthermore epitomized in the emerging wealth of ‘social 
cost’- or ‘cost-effectiveness’-based research of either un-
treated illicit opioid use or opioid pharmacotherapy treat-
ment  [11, 22–25] . 
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 With its primary focus on social outcomes as the ex-
pected effects of an intervention that supposedly aims at 
a ‘brain-related medical disorder’  [10] , MMT presents a 
unique case in the framing of clinical intervention and 
evaluation practice. In fact, no other medical interven-
tion for chronic disease with relapse potential we are 
aware of shares such a framework. As just one example, 
the respectively deﬁ ned major endpoints for clinical trials 
of major depression therapy are not framed primarily as 
social but as individual beneﬁ ts (see the outcomes of the 
respective Cochrane review at www.cochrane.org). 
 Evaluation of MMT has persistently stuck with soci-
etal measures of ‘success’ that are heavily inﬂ uenced by 
societal determinants (rather than status or behavior an-
chored mainly in the patient’s discretion, especially in the 
short-term). For example, ‘employment’, as a key mea-
sure, depends on a multitude of extrinsic parameters (like 
skills and education, labor market, etc.) far removed from 
the patient’s drug use status or biomedical condition. 
Similarly, the measure of ‘crime’ (especially as indicated 
by institutional data) depends predominantly on the dy-
namics of law and enforcement  [26, 27] . 
 Furthermore, MMT evaluation approaches actually fo-
cusing on a patient-centered perception of health and well-
being have played a completely marginal role within the 
considerable span of MMT research. ‘Quality of life’ (QoL) 
perspectives have emerged as an increasingly relevant 
framework within general clinical research elsewhere, in-
cluding cancer, AIDS and psychiatry over the past 25 years 
 [28, 29] . Yet, a recent review of QoL perspectives within 
opioid pharmacotherapy treatment has revealed that this 
literature is limited to only 6 systematic studies, many of 
which struggle with methodological shortcomings  [30] . Be-
sides its peculiar marriage of biomedical causes with social 
engineering, MMT practice and research is, furthermore, 
almost entirely devoid of those perspectives of patient-cen-
tered health and well-being which have set new standards 
in the general ﬁ eld of clinical research  [30] . 
 Short-Sighted? The Partial and Short-Term 
Impact of MMT 
 Even a rather crude look at different empirical indica-
tors of MMT’s effectiveness indicates potentially funda-
mental shortcomings in the way the impact of MMT on 
its target population has traditionally been assessed. The 
conventional approaches to evaluate MMT are built on 
methodologies that largely ignore patient-centered views 
and on program dynamics that systematically de-select 
courses of treatment not producing MMT’s desired ef-
fects. From a different point of view, MMT’s effective-
ness, when assessed on the basis of qualitative and patient-
centered data, appears rather limited and short-term. 
 One of the key credos of MMT has been that treatment 
success or beneﬁ t is positively correlated with the ‘dura-
tion of treatment’  [20] , and that the length of the patient’s 
participation in treatment is a key predictor of positive 
results  [15, 31] . The logic as well as the mechanics behind 
these principles appear peculiar and shaped by tautologi-
cal dynamics. MMT programs operationalize structures 
of norms and sanctions that systematically penalize and 
exclude patients who do not comply with the various rules 
of treatment – which at the same time constitute MMT’s 
main success indicators. One preeminent example is the 
criteria concerning illicit opioid or other drug use. Many 
MMT programs operate with urinalysis tests, screening 
patients for continued illicit drug use  [32] . In case of re-
peated noncompliance, patients usually receive some 
form of penalization, up to an ‘involuntary discharge’ and 
then appear as ‘dropouts’ in program statistics. Other rea-
sons for dismissal include nonattendance of psychosocial 
treatment, missing methadone pick-ups or clinic appoint-
ments or the diversion of prescribed methadone  [33–36] . 
Again, these rules are very speciﬁ c to MMT – no diabet-
ic or AIDS patient would be penalized by the treatment 
provider for not complying with the prescribed treatment 
regimen (even though compliance rates are similar to 
MMT). It is generally accepted knowledge that it is the 
‘most difﬁ cult’ or noncompliant patients who leave MMT 
disproportionately and early on in treatment. 
 In fact, the criticism of assessments of MMT’s effec-
tiveness being selective and skewed is not new. Long ago, 
a widely ignored paper concluded that in key programs 
MMT’s ‘pro-social changes [...] were limited almost ex-
clusively to “the minority” of the patients who were re-
tained in the program for more than 3 years’ and that ‘the 
bulk of “reports on MMT’s effectiveness” are based on 
analytic methods so weak that almost no conclusion can 
be drawn from them’  [37] . In the current context, it is thus 
crucial to pay attention to the extensive empirical data 
showing that patient retention in MMT programs (mea-
sured at the 1-year point) is the exception rather than the 
rule. In a review of recent key studies indicating patient 
retention in MMT programs, National Institute on Drug 
Abuse reports a mean retention rate of 39.8% at 1 year 
(range: 25–60%).  [9] Conclusively, the review describes 
the evidence on retention rates in MMT as suggesting that 
‘about one third of the patients […] remain for at least 1 
year after admission’  [9] . In a similar review, Bertschy 
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 [21] reports a 1-year retention rate of 54.4% (range: 29–
73%). This crude analysis presents us with the important 
insight that at least half of patients admitted to MMT 
have, for various reasons, left or been excluded from 
treatment, and are, on the basis of current practices, not 
part of any research analysis  [20, 38, 39] . 
 The limitations of MMT also become evident from the 
perspective of patient-centered QoL assessments of treat-
ment effects  [30] . The very few studies that have con-
ducted systematic and standardized QoL assessments of 
MMT patients over time over the course of treatment 
provide important insights  [40–42] . MMT patients re-
tained in treatment indicate only moderate improve-
ments in QoL status – from low original levels – after the 
initiation of treatment. However, these improvements 
only occur in the very ﬁ rst few months of treatment. After 
that, QoL levels in these studies plateau out or even re-
verse and thus constitute a short-term phenomenon  [40–
42] . Torrens et al.  [42, 43] , in the only long-term QoL 
follow-up study of MMT patients, illustrate that even 
within the limited proportion of retained patients (1 
year = 61%; 3 years = 47%), the vast bulk of QoL improve-
ments occurred within the ﬁ rst 30 days of treatment, 
some between month 1 and 12, and no measurable im-
provements between month 12 and 36. 
 There are also critical, yet often ignored dynamics in-
trinsic to the treatment itself which point to MMT’s lim-
ited effectiveness for some illicit opioid users. The lim-
ited patient-centered literature  [44–46] illustrates the 
broad ‘dysphoric’ dynamics of methadone and how this 
can negatively impact on patients’ lives. Patient accounts 
have described the side effects of methadone as severely 
discomforting, disabling, numbing and tiring, in essence 
providing a powerful ‘sedation’ or ‘blockade’ effect bar-
ring them from heroin’s desired qualities  [47–50] . The 
mechanics and settings of MMT may also add a negative 
effect on the social and interpersonal aspects MMT pa-
tients’ lives. The loss of the daily thrill, hassle and chal-
lenges of illicit drug scoring, the absence of a job, skills or 
employment prospects, unstable personal, social, ﬁ nan-
cial or housing situations plus the rigorous, yet often pu-
nitive routine of MMT program requirements (including 
daily visits, urine tests, psychosocial treatment) have 
been described as putting a debilitating and demotivating 
face on many patients’ daily life realities, and thus reduc-
ing their chances of retention and success in treatment 
 [44, 51] . 
 With the above data, we would like to offer the interim 
conclusion that current knowledge and beliefs about the 
‘effectiveness’ of MMT treatment are based on the one 
hand on highly selective and partial assessment perspec-
tives, while on the other hand they appear to ignore the 
evidence of severe limitations as indicated by patient-
centered evaluation methods (i.e., QoL). 
 MMT: Effective Treatment or Selection of 
Compliance? 
 Efﬁ cacy is traditionally assessed in randomized clini-
cal trials (RCT). Even though the extent of literature on 
MMT is large (a MEDLINE search on methadone and 
maintenance in June 2001 revealed 1,825 hits), there are 
very few RCTs on efﬁ cacy of MMT vs. placebo  [8, 19, 
52–54] . While these trials show signiﬁ cant improvements 
in outcomes such as illegal drug use, reincarceration, or 
treatment retention, they are plagued by various method-
ological problems. Most studies are based on small num-
bers of subjects, follow-up times are short (mostly 12 
months or shorter), and all RCTs were conducted in coun-
tries where MMT at the time was the only pharmaco-
therapy available, and with limited availability. Thus, 
under these circumstances, retention rates may have been 
artiﬁ cially pushed higher as dropping out from the trial 
may have meant the subjects’ loss of a unique opportu-
nity for pharmacotherapy  [55] . 
 The other evidence usually cited to show MMT effec-
tiveness consists of observational studies. The study by 
Ball and Ross  [15] , another often-cited ‘classic’ on the ef-
fectiveness of MMT, has the following methodological 
problems: it was conducted in a system (US) with severe 
lack of adequate treatment alternatives, and the sampling 
overemphasized cases with long retention in treatment 
(35.5% were in treatment for 3 years and over, and an-
other 34.4% for 1 up to 2.9 years). Thus, the effectiveness 
results could be mainly interpreted as showing effects for 
those who were compliant with the (often very strict) re-
gimes of the treatment centers. The GAO study  [56] is 
one of the largest MMT studies conducted. It obtained 
data on narcotics use from 5,600 patients enrolled in 
MMT for at least 6 months. However, such a design, 
again, favored positive outcomes, as all the early dropouts 
(54%) were not included in the statistical analysis, 10 out 
of 24 programs failed to meet the standard for success, 
since less than 20% of patients enrolled for at least 6 
months were still injecting heroin  [56] . Secondary analy-
sis  [57] provided evidence that mean dose of methadone 
predicted both retention and continued illicit heroin use, 
and the results were interpreted as supporting the as-
sumption of effectiveness of MMT  [20] . 
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 In sum, the quality and methodological standards of 
the evidence on the effectiveness of MMT are limited and 
far less impressive than usually cited  [10, 20, 58] . The 
minority of patients who make it through the initial 18–
24 months of MMT present good odds of constituting a 
cluster whose treatment performance indicates improve-
ment on the standard outcome measures. It is not clear, 
however, whether these improvements demonstrate ‘true’ 
treatment effects or are a result of systematic selection of 
compliant patients. 
 MMT and ‘Other Drug Use’: Ambiguous 
Effects and Neglected Evidence 
 Patients’ other drug use (mostly cocaine, alcohol, mar-
ijuana, benzodiazepines and nicotine) during MMT has 
become increasingly important as a treatment evaluation 
endpoint. This development has occurred for several rea-
sons. One of the pressing reasons has been that ‘other drug 
use’, especially cocaine use, has become more prevalent 
among opioid addicts since the 1980s. Also, MMT has 
been utilized increasingly for addicts with polydrug de-
pendence  [38, 59, 60] . 
 While many reviews state that methadone is also ef-
fective in reducing cocaine consumption  [10, 20, 61] , re-
sults supporting this claim are ambivalent at best. In one 
of the RCTs cited above  [19] no signiﬁ cant cocaine reduc-
tion effect emerged, e.g. the MMT group had no signiﬁ -
cantly different results than the control group. Once 
again, studies cited regularly supporting the effectiveness 
of MMT for cocaine use reduction are burdened with 
methodological problems  [38, 61] . The critical issue con-
cerns study designs that do not adjust for dropouts. An 
illustration: The outpatient methadone treatment out-
come data of Hubbard et al.  [62] reﬂ ects a 20% reduction 
in weekly cocaine use among patients 1 year after treat-
ment entry. However, the study sample size diminished 
through attrition from 1,203 patients at treatment admis-
sion to 727 patients at 1-year follow-up, with 476 patients 
(39.6%) having dropped out of treatment over the course 
of the ﬁ rst year. 
 The implications of this problem can be illustrated by 
two hypothetical, yet realistic better-and-worse scenario 
calculations. If 80% of the 476 treatment dropouts in the 
study by Hubbard et al.  [62] still used cocaine at the point 
of follow-up, then 45% of the total base sample (n = 1,203) 
would be using cocaine after 1 year of treatment. This ﬁ rst 
hypothetical scenario would indicate an overall increase 
in cocaine use over time when taking into account the 
behavior of all original patients. In a second hypothetical 
calculation, if 60% of the 476 treatment dropouts still 
used cocaine, then 37% of the total base sample would be 
using cocaine after 1 year of treatment. This second hy-
pothetical situation would mean a minimal reduction of 
cocaine use in the treatment sample over preadmission 
rates, likely below statistical signiﬁ cance levels. Intent-to-
treat analysis where a negative outcome is assumed for 
all dropouts would thus lead to a conclusion that a marked 
increase in cocaine use occurred for the sample over the 
course of study. 
 In the study by Ball and Ross  [15] , frequently cited to 
support the effectiveness of MMT at reducing cocaine 
use, the sample was skewed in a way to include many pa-
tients with long treatment histories. In short, such studies 
show that individuals retained in treatment for longer 
times can reduce their cocaine use, but they lack untreat-
ed controls and patients’ drug use histories. Therefore, 
these studies cannot exclude the alternative hypothesis 
that these positive ﬁ ndings are simply the result of sample 
selection effects. In untreated controls, there may well be 
a minority indicating cocaine use reductions, yet usually 
no empirical information is available about them. 
 Other studies have reported mixed effects or even in-
creases in patients’ cocaine use during MMT. In the Van-
couver VIDUS cohort of injection drug users, cocaine use 
declined from 60 to 37%, and speedball use decreased 
from 28 to 22%, but crack use increased from 18 to 36% 
for the total cohort over an observation period of 3 years 
among a sample of 174 subjects who were consistently 
enrolled in MMT. However, a snapshot comparison be-
tween the subjects in MMT (174) with those not in MMT 
(882) showed that drug use was essentially the same in 
the two groups  [63] . Best et al.  [64] found increased use 
of crack cocaine over the course of MMT, and 16.5% of 
patients (based on 91% follow-up rate) initiated crack co-
caine use in the ﬁ rst 6 months of treatment. This example 
is also important because other examples of increased 
cocaine use occurred during the time when cocaine be-
came more available in the respective sociocultural set-
ting, and thus comparisons may be confounded by extrin-
sic determinants of time and place  [65] . 
 In sum, we have an ambivalent picture of the effects of 
MMT on the prevalence of cocaine use among patients. 
Cautious interpretation of the available wealth of empiri-
cal data would suggest no clear overall effect. The same 
seems true for other substances for which studies have 
found increases in use during MMT even for treatment 
‘responders’  [66, 67] . But overall, based on methodologi-
cally weak studies, evidence for decreases, increases and 
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stable levels of other drug use can be found among MMT 
patients. Since methodological weaknesses tend to favor 
positive results (e.g., there is no reason to assume that the 
select samples of compliant patients are doing worse than 
the dropouts), intent-to-treat analysis with the assumption 
of negative results for dropouts would usually result in 
ﬁ ndings of no changes or increases. 
 The Eye That Might See: Comorbidity and 
Self-Medication 
 Even when the pure ‘biochemical intervention’ per-
spective of MMT is assumed, there is no rational basis 
for expecting that this intervention will lead to an altera-
tion of the patient’s opioid dependence status or a reduc-
tion of other non-opioid drug use. Nevertheless, these hy-
pothetical effects of reduced illicit drug use have a long 
history of being ﬂ agged as a major beneﬁ t of MMT, and 
frequently data are presented that demonstrate MMT’s 
supposed effectiveness in producing these effects  [19, 68, 
69] . Our above methodological critique suggested that 
there are no solid empirical grounds to assert that MMT 
is consistently effective in reducing illicit drug use among 
patients. In fact, sporadic evidence suggests that the con-
trary effect may be true. 
 Although there has been a debate about the measuring 
of the prevalence of psychiatric conditions among drug 
users in treatment institutions  [70] and about the causal-
ity of covariation between psychiatric and substance use 
disorders  [71] , there is substantial evidence that such 
symptoms are disproportionately prevalent and nonran-
domly distributed among illicit opioid users. For exam-
ple, the ECA study  [14] documented on the basis of a 
large-scale representative population survey that psychi-
atric comorbidity prevalence amounted to as much as 
65.2% in illicit opioid user populations and the preva-
lence was 6.7 times that of the general population. In par-
ticular, anxiety and mood disorders were prevalent in 
nearly one third of subjects, and psychotic features oc-
curred in more than 10%  [14, 72, 73] . Various studies of 
opioid or injection drug user cohorts suggested that ap-
proximately half of the individuals assessed met the di-
agnostic criteria for major depression as the primary psy-
chiatric indication in this subpopulation  [73–77] . Almost 
two thirds of a sample of drug using admissions cases to 
a psychiatric facility stated that they used illicit substanc-
es (opioids, cocaine or sedative-hypnotics) in response to 
‘feeling depressed’  [78] . Abraham and Fava  [79] found a 
temporal correlation between psychiatric mood disorder 
symptoms and subsequent cocaine and alcohol depen-
dence. The prevalence of use of stimulants among people 
with schizophrenia has been found to be signiﬁ cantly 
greater than that of control populations  [80] , and depres-
sive features have been identiﬁ ed as a major determinant 
for smoking as well as an inﬂ uence on the success rate of 
quitting attempts  [81] . A number of studies found that 
mood and anxiety disorders are a signiﬁ cant predictor of 
illicit drug use for ‘self-medication’ purposes  [78, 82] . 
 While the high coprevalence of narcotic or stimulant 
drug dependence and psychiatric disorder symptoms is 
convincingly evidenced, it is Khantzian’s  [83] seminal 
work that has provided fundamental analysis on the cor-
relation between speciﬁ c psychiatric conditions and cat-
egories of drug dependence. Essentially, Khantzian sug-
gests that drug-dependent individuals are not only pre-
disposed to the use of psychoactive substances in order 
to ‘medicate themselves for a range of psychiatric prob-
lems and painful emotional states’  [83] , but furthermore 
are ‘attracted to and choose substances’  [84] in order to 
cope with or ‘self-medicate’ speciﬁ c or distinct mental 
health conditions. This appears particularly relevant for 
the subgroup of patients for whom psychoactive drug use 
has been empirically found to be a causal consequence of 
psychiatric symptoms  [71, 85] . For instance, some drug-
dependent people seek out opioids to calm underlying 
feelings of anger, rage or aggression – utilizing the ‘anal-
gesic properties’ of the substance in a broad sense. Co-
caine is sought out primarily by some people for the drug’s 
ability to alleviate psychological distress associated with 
depression and attention deﬁ cit disorder  [79, 83, 86] . 
 Looking from two angles, the self-medication perspec-
tive seems essential for a constructive understanding and 
synthesis of our observations in regard to the current re-
alities of MMT. First, if one accepts the proposed role of 
a fundamental causal contribution of psychiatric disor-
ders to the substance use patterns in at least some illicit 
opioid users, the aims of MMT in its current framework 
and practice are off target. The ‘chemical intervention’ 
component of MMT is not a suitable or effective response 
to any of the various primary psychiatric symptoms ob-
served in the majority of illicit opioid users. The much 
emphasized ‘psychosocial treatment’ components in 
MMT  [15, 87] – delivered predominantly in the form of 
occasional individual or group counseling, skills develop-
ment, self-help – cannot be considered as adequate efforts 
to provide therapy for illicit substance users’ long-stand-
ing psychiatric disorders, such as mood and anxiety dis-
orders, schizophrenia or other psychotic disorders. As 
such, MMT in its current approach, may simply be ad-
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dressing surface symptoms, while neglecting the funda-
mental processes underneath the pathological etiology of 
illicit opioid and other drug use. 
 Conclusions: Opioid Pharmacotherapy 
Treatment – Quo Vadis? 
 In this paper, we have critiqued the conceptual funda-
mentals as well as evaluation approaches and evidence of 
almost four decades of MMT, the central treatment mo-
dality for the treatment of hundreds of thousands of opi-
oid-dependent individuals in the Western world. Our ba-
sic conclusions are that fundamental rethinking is needed 
in order to achieve meaningful progress of opioid phar-
macotherapy practice in the 21st century. 
 One of the central contentions emerging from our re-
view is that it is principally and practically not sensical 
to maintain opioid pharmacotherapy as an exotic bul-
wark of medicine artiﬁ cially designed to serve primarily 
societal goals, while emphasizing patient-centered cir-
cumstances, well-being and QoL. There is neither a prag-
matic rationale nor good reason to expect that biochemi-
cal treatment for opioid dependence, as provided by 
MMT, will produce ‘social betterment’ for individuals or 
populations as socially marginalized or disadvantaged as 
most illicit opioid users. Hardly any of the longstanding 
main goals of MMT have a direct or necessary link to pa-
tients’ perceived well-being or QoL, which has become a 
central measure and guiding pole for the assessment of 
treatment for chronic illnesses  [88, 89] . Although concep-
tual and sensitivity questions exist with regard to the ap-
propriate measuring of QoL  [30, 90] , these perspectives 
– while acknowledging certain utilitarian limitations – 
should form the basis for future assessment of whether 
we are providing ‘good’ or ‘bad’ treatment in the form of 
MMT and beyond. Physical and mental health status and 
improvement – measured by standard indicators as well 
as the patient’s experiences – must present the key and 
authoritative measures for the effects and quality of MMT 
care. Meaningful analysis of treatment effectiveness 
should use comparisons with a control condition (with 
RCT as the desirable standard) and utilize intent-to-treat 
methodology to exclude effects produced by self-selec-
tion. While the former presents ethical dilemmas, espe-
cially with populations like substance-dependent pa-
tients, it is a minimal scientiﬁ c standard so far drasti-
cally ignored in hundreds of MMT outcome studies. 
 We have, furthermore, suggested the necessity of un-
derstanding illicit opioid and other drug use during opi-
oid pharmacotherapy within the psychiatric comorbidity 
and self-medication framework. If taken seriously in the 
real life context of illicit opioid use and treatment, this 
perspective would not only eliminate the challenging ex-
pectation of reductions of cocaine and other drug use 
among MMT patients, but also provide an explanation 
for why such behaviors may become exacerbated during 
treatment for some. In fact, the clinical MMT research 
ﬁ eld has for a long time presented clues that strengthen 
these observations and help to support conclusions for 
clinical practice. It is becoming more evident that MMT 
typically hosts distinct clusters of patients with different 
patterns and needs in terms of psychiatric and self-medi-
cation dynamics determining their drug use proﬁ le. Stud-
ies prior to the 1980s on the effectiveness of MMT typi-
cally noted substantial increases in the consumption of 
alcohol. In certain patient subclusters, increases in alco-
hol use during treatment are not dissimilar to cocaine in 
terms of psychoactive effect proﬁ les, properties and dy-
namics, especially from a self-medication point of view 
 [79, 91] . Viewed within the self-medication framework, 
empirical categorization of MMT patients into distinct 
psychiatric indication clusters, as demonstrated by Strain 
et al.  [77] , meaningfully complements and supports these 
conclusions. These insights, taken in synthesis, suggest 
that we ought to become much more sensitive in our un-
derstanding of opioid and other drug use disorders as 
driven and inﬂ uenced by psychiatric-structural disposi-
tions, for which opioid pharmacotherapy alone cannot be 
expected to provide a sufﬁ cient intervention. 
 Thus, what is necessary are realistic and differentiated 
approaches for the future of meaningful and patient-cen-
tered opioid pharmacotherapy with the principal goal of 
maximized patient health and well-being. First, we need 
thorough and comprehensive empirical data on the self-
medication dynamics of opioid users in and out of treat-
ment. Secondly, the dynamics of distinct patterns and 
needs with regard to psychiatric comorbidity proﬁ les in 
opioid dependence patients emphasize more strongly 
than before the need for differentiated treatment regimes 
within the broadening realm of opioid pharmacotherapy 
beyond conventional MMT. It may very well be the case 
that new regimes emerging in the increasingly diverse opi-
oid pharmacotherapy landscape (including buprenor-
phine combinations, morphine, heroin, Dilaudid  [18, 92] 
provide more sensitive and desirable responses in certain 
patient groups with diverse dispositions than traditional 
MMT. 
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Comment
A. Uchtenhagen
Zurich
In view of the worldwide application and ongoing
expansion of opiate replacement therapies, there is much
interest in sound scientific evidence regarding the merits
and shortcomings of those therapies. Many of the argu-
ments in Fischer’s review of methadone maintenance
treatment (MMT) could apply for other replacement ther-
apies as well, and therefore it is all the more appropriate to
discuss his arguments.
First, the ‘cross-eyed mission’: methadone mainte-
nance as a biomedical treatment for social rehabilitation
is far from being ‘unique’. Most pharmacological inter-
ventions in psychiatry do not only focus on the patient’s
subjective health status or well-being, but on behavior
that is impeding social functioning and/or inviting con-
flicts with others. Antidepressant, antianxiety and anti-
psychotic medications not only relieve symptoms, but
also the many negative consequences of patient’s behav-
ior in the social context. Improved well-being may even
be a consequence of improved social functioning and less
conflict. It is a misleading approach to separate the sub-
jective from the social aspects of psychiatric morbidity, as
there are many interactive processes to be considered, and
drug dependence is part of psychiatric morbidity.
However, it is true that quality of life (QoL) is an
often neglected issue in methadone maintenance re-
search. But if the studies mentioned in Fischer’s article
indicate improvements during the first few months in
treatment, this should be considered to be a rather posi-
tive effect, in line with rapid improvements in health sta-
tus. I may add that it would make more sense to assess
more precisely what has improved in the subjective situ-
ation of maintenance patients and what has eventually
worsened: from clinical experience one would expect im-
provements in health status and relief from impediments
that are related to the daily need to satisfy the drug crav-
ing and to find the necessary means, but also a confron-
tation with many problems covered up so far and with
the often depressing experience of what has been missed
in life. Also the side effects of medications, the new des-
pondency on the treatment program, the social isolation
after loosening the ties to the drug scene are factors that
reduce QoL. Without such a differentiation of positive
and negative factors, assessment of QoL scores is of lim-
ited value.
The methodological shortcomings of evaluation stud-
ies are a serious issue. However, in a meta-analysis of 6
randomized controlled studies, an updated Cochrane re-
view (known in medicine for their rigorous methodologi-
cal standards) has evidenced that methadone appeared
statistically more effective than non-pharmacological ap-
proaches in retaining patients in treatment and in the sup-
pression of heroin use, but not statistically in criminal
activity [Mattick et al., 2004]. In a recent randomized
controlled study on methadone maintenance in prison as
compared to untreated controls (waiting list), objective
and subjective measures of opioid use were significantly
reduced in the methadone group, as was sharing of
syringes [Dolan et al., 2003].
Observational cohort studies often suffer from a
weakness mentioned in Fischer’s article: in contrast to
an intention-to-treat design, many base their statistics on
those who remain in treatment during the follow-up peri-
od. However, the National Treatment Outcome Re-
search Study in England has published the findings of a
5-year follow-up on a randomly selected sample from 54
programs included in the study (drug-free residential,
community-based methadone maintenance and metha-
done reduction), independent of length of stay in the
program and retention. The outcome of community-
based services using methadone is equivalent to the out-
come of residential treatments and includes major im-
provements in many domains in comparison to baseline
data: regular heroin use; non-prescribed methadone use;
regular non-prescribed benzodiazepine use; regular co-
caine powder use; injecting and sharing; psychological
health symptoms; suicidal ideation, and selling drugs.
For crack cocaine use and regular amphetamine use, out-
comes were better in the sample from community-based
services. Psychological health symptoms, suicidal idea-
tion, acquisitive crime and selling drugs showed a
marked decrease at year 2 and then a moderate increase
until years 4–5, but did not reach the base-line high, for
patients from community-based and from residential
services [Gossop et al., 2001]. Some major lessons come
from this study: patients in residential treatment in gen-
eral had more serious problems than those in the outpa-
tient programs, but the overall outcomes from both set-
tings are quite similar. While three quarters of metha-
done patients showed a good response to treatment, one
quarter did not and is a matter of concern. However, the
range and magnitude of positive outcomes from metha-
done programs complement the findings from random-
ized controlled studies.
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An essential part of the health effects of replacement
therapies with oral medications is the prevention of
blood-born diseases and their progression. A review of the
evidence includes:
(1) A reduction in HIV seroconversion rates in HIV-
negative opiate users in comparison to users out of treat-
ment [Abdul-Quader et al., 1987; Schoenbaum et al.,
1989; Chaisson et al., 1989; Blix and Grönbladh, 1991;
Metzger et al., 1993; Moss et al., 1994; Serpelloni et al.,
1994; Gibson et al., 1999].
(2) A reduction in unsafe injection practices, especially
needle sharing (a meta-analysis of 8 studies on 1,781 par-
ticipants comparing MMT patients with users out of
treatment, or comparing pre-post values, various dura-
tions of treatment or continuous versus interrupted treat-
ment, presented by Marsch [1998], and a recent review of
33 studies including over 17,000 participants by So-
renson and Copeland [2000]).
(3) A better compliance with anti-retroviral medica-
tion [Avants et al., 2001] and a reduction in the progres-
sion of HIV-related disease [Weber et al., 1990].
Finally, a reduction in mortality rates is documented
to be significant as compared to out of treatment heroin
addicts [Stenbacka et al., 1998], but methodological prob-
lems are mentioned in a meta-analysis of mortality stud-
ies [Caplehorn et al., 1996]. However, there is a signifi-
cant increase in overdose mortality in patients who left
methadone maintenance [Appel et al., 2000; Langendam
et al., 2001] and again a decrease after readmission [Grön-
bladh et al., 1990].
Both seroconversions and fatalities occur in the early
phase of maintenance treatment. While seroconversions
are related to infections acquired before starting treat-
ment or to continued injecting behavior during the first
months of treatment, fatal overdose may result from inad-
equate dosaging or synergistic effects from methadone
and other drugs [Caplehorn, 1998]. As in the medical
management of other chronic conditions (such as anorex-
ia, rheumatic disorders, deficits from brain injury, etc.),
methadone maintenance needs some time to become
effective or to stabilize initial improvements. Good reten-
tion therefore is a primary objective, and negative out-
comes in early dropouts should not account for a discredi-
tation of the treatment per se.
The increase in replacement therapies (mainly metha-
done and buprenorphine maintenance) during the last
decade is to be seen on the background of the threat from
blood-born infectious disease and therefore driven by a
priority public health interest. The evidence summarized
here is much in support of those efforts, especially in
countries where opiate injecting and its adverse effects are
on the rise and where replacement therapies are an instru-
ment to reduce the speed of the epidemic. Fischer’s criti-
cal review should not be misused to discredit those efforts;
it is welcomed however to further improve future research
on effectiveness.
References
Abdul-Quader AS, Friedman SR, Des Jarlais D, Marmor MM, Maslansky MR,
Bartelme S: Methadone maintenance and behavior by intravenous drug
users that can transmit HIV. Contemp Drug Probl 1987;14:425–434.
Appel PW, Joseph H, Richman BL: Causes and rates of death among metha-
done maintenance patients before and after the onset of the HIV/AIDS
epidemic. Mount Sinai J Med 2000;67:444–451.
Avants SK, Margolin A, Warburton LA, Hawkins KA, Shi J: Predictors of non-
adherence to HIV-related medication regimens during methadone stabilis-
ation. Am J Addict 2001;10:69–78.
Blix O, Grönbladh L: The impact of methadone maintenance treatment on the
spread of HIV among i.v. heroin addicts in Sweden; in Loimer N, Schmid
R, Springer A (eds): Drug Addiction and Aids. Vienna, Springer, 1991, pp
200–205.
Caplehorn JRM: Deaths in the first two weeks of maintenance in NSW in 1994:
Identifying cases of iatrogenic methadone toxicity. Drug Alcohol Rev 1998;
17:9–18.
Caplehorn JRM, Dalton MS, Haldar F, et al: Methadone maintenance and
addict’s risk of fatal heroin overdose. Subst Use Misuse 1996;31:177–196.
Chaisson RE, Bacchetti P, Osmond D, Brodie B, Sande MA, Moss AR: Cocaine
use and HIV infection in intravenous drug users in San Francisco. JAMA
1989;261:561–565.
Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD: A ran-
domized controlled trial of methadone maintenance treatment versus wait
list control in an Australian prison system. Drug Alcohol Depend 2003;72:
59–65.
Gibson DR, Flynn NM, McCarthy JJ: Effectiveness of methadone treatment in
reducing HIV risk behavior and HIV seroconversion among injecting drug
users (editorial). AIDS 1999;13:1807–1818.
Gossop M, Marsden J, Stewart D, Treacy S: Outcomes after methadone main-
tenance and methadone reduction treatments: Two-year follow-up results
from the National Treatment Outcome Research Study. Drug Alcohol
Depend 2001;62:255–264.
Grönbladh L, Ohlund LS, Gunne LM: Mortality in heroin addiction: Impact of
methadone treatment. Acta Psychiatr Scand 1990;82:223–227.
Langendam MW, Van Brussel HA, Coutinho RA, Van Ameijden EJC: The
impact of harm-reduction-based methadone treatment on mortality among
heroin users. Am J Publ Health 2001;91:774–780.
Marsch LA: The efficacy of methadone maintenance interventions in reducing
illicit opiate use, HIV risk behavior and criminality: A meta-analysis.
Addiction 1998;93:515–532.
Mattick RP, Breen C, Kimber J, Davoli M: Methadone maintenance therapy
versus no opioid replacement therapy for opioid dependence (Cochrane
Review). The Cochrane Library. Chichester, Wiley, 2004, issue 2.
Metzger DS, Woody GE, McLellan AT: Human immunodeficiency virus sero-
conversion among intravenous drug users in- and out-of-treatment: An 18-
month prospective follow-up. J Acquir Immune Defic Syndr 1993;6:1049–
1056.
Moss AR, Vranizan K, Gorter R, Bachetti P, Watters J, Osmond D: HIV sero-
conversion in intravenous drug users in San Francisco 1985–1990. AIDS
1994;8:223–231.
Schoenbaum EE, Hartel D, Selwyn PA, Klein RS, Davenny K, Rogers M,
Feiner C, Friedland G: Risk factors for human immunodeficiency virus
infection in intravenous drug users. N Engl J Med 1989;321:874–879.
Serpelloni G, Carrieri MP, Rezza G, Morganti S, Gomma M, Binkin N: Metha-
done treatment as a determinant of HIV risk reduction among injecting
drug users: A nested case control study. AIDS Care 1994;16:215–220.
Sorenson L, Copeland AM: Drug abuse treatment as an HIV prevention strate-
gy: A review. Drug Alcohol Depend 2000;59:17–31.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.2
30
.2
30
 - 
7/
31
/2
01
4 
12
:4
9:
38
 P
M
12 Eur Addict Res 2005;11:1–14 Fischer/Rehm/Kim/Kirst
Stenbacka M, Leifman A, Romelsiö A: The impact of methadone on consump-
tion of inpatient care and mortality, with special reference to HIV status.
Subst Use Misuse 1998;33:2819–2834.
Weber R, Ledergerber B, Opravil M, Siegenthaler W, Lüthy R: Progression of
HIV infection in misusers of injected drugs who stop injecting or follow a
programme of maintenance treatment with methadone. BMJ 1990;301:
1362–1365.
Comment
Robert G. Newman
New York, N.Y.
In his ‘Conceptual and Empirical Critique of Metha-
done Maintenance Treatment (MMT),’ Fischer raises a
number of valid criticisms of the manner in which MMT
is provided, its goals, and the parameters used to evaluate
outcome. Unfortunately, he goes on to reveal many of the
same distorted perspectives with which he finds fault.
With regard to goals and outcome measures, Fischer
characterizes as a ‘cross-eyed mission ... the provision of
biomedical treatment for social rehabilitation’. To the
extent the interests of the community at large are given
priority over the needs and wishes of the individual
patient, the criticism is valid. But empirical data – and
common sense – attest to the concomitant benefits for
society as a whole when a heroin addict curtails or stops
his/her illicit opiate use. It should also be noted that opti-
mal medical management of any disease focuses on needs
and challenges that transcend the strictly physical aspects
of the individual patient’s disease. Indeed, Fischer him-
self, after expressing his skepticism over ‘social rehabilita-
tion’ as a goal of treatment, goes on to disparage the
limited effectiveness of MMT in enhancing ‘quality
of life’, addressing ‘long-standing psychiatric disorders’,
etc. – limitations that surely apply to the management of
all chronic medical conditions.
In describing the ‘“dysphoric” dynamics of metha-
done’, Fischer fails to distinguish between the arbitrarily
imposed policies and practices of providers and the phar-
macological effects of the medication. Dysphoria is inevi-
table in settings where clinicians ‘systematically penalize
and exclude patients who do not comply with the various
rules of treatment’. For example, Fischer is absolutely cor-
rect in condemning the counter-therapeutic and counter-
intuitive use of laboratory tests (urine toxicology) to iden-
tify and punish drug use – the pathognomonic feature of
the disease being treated. It is equally counter-therapeutic
to punish failure to accept ‘psychosocial treatment’,
missed appointments, etc. Policies such as these reflect
therapeutic tyranny, rather than the characteristics of the
medication. They tell us nothing of its positive and nega-
tive effects when used in accord with usual clinical and
ethical standards of medical care.
On a somewhat technical note, Fischer seems to con-
fuse two distinct pharmacological actions of MMT, each
of which contributes to its effectiveness. One is the devel-
opment of a high degree of tolerance (‘narcotic blockade’)
that prevents the euphorigenic and most other effects of
all opiates, including the maintenance doses of metha-
done itself. The other pharmacological effect is the dimin-
ution or extinction of ‘craving’ for opiates which is com-
monly reported by patients. Fischer attacks a strawman
when he challenges the thesis that ‘opioid “narcotic block-
ade” (in the form of MMT) would alleviate a human
agent’s craving’.
Fischer is also off the mark in his comments on patient
retention in MMT. One reference he cites is of a series of
reports in which the median 1-year retention rate is 40%;
another referenced program retained almost half its pa-
tients for 3 years. Even the lowest MMT rates, however,
compare very favorably with those of any other addiction
treatment modality. The MMT experience in this regard
is especially remarkable in the face of the widespread pro-
gram policies, discussed previously, that result in ‘dyspho-
ria’, punishment and treatment termination.
Finally, Fischer is sadly – tragically! – mistaken in the
degree of acceptance he attributes to MMT. He com-
ments: ‘Over the years, general shortcomings of MMT
have been recognized and debated, but none of them have
[sic!] managed to effectively challenge the predominant
view of MMT as being “effective”.’ In fact, despite many
hundreds of consistent reports of benefits associated with
MMT that have appeared for decades from throughout
the world, a great many countries continue to ban metha-
done prescribing altogether, and virtually all the rest
impose severe restrictions that are without parallel, and
that preclude the majority of opiate-dependent individu-
als from having access to care that they want and need.
Russia is a case in point, adamantly rejecting methadone
despite an estimated 2 million addicts, rampant HIV,
tuberculosis and hepatitis infection, and a burgeoning
addict population in prison. Nor is America, where the
concept and practice of methadone maintenance were
introduced exactly 40 years ago, that much different:
methadone is the only medication in the US pharmaco-
poeia that cannot be prescribed by community-based
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practitioners, and the programs that have been given the
monopoly on its use can accommodate no more than 15–
20% of the estimated heroin addict population.
We know that methadone offers help and hope to a
large proportion of those dependent on opiates. We also
know that without MMT, the vast majority will be aban-
doned and become victims of the heightened morbidity
and mortality with which addiction is associated. And yet,
the prospect that MMT will be permitted to fulfill its life-
enhancing and life-saving potential remains exceedingly
slim. Fischer’s article won’t help!
Reply
Response to Commentaries by
A. Uchtenhagen and R. Newman
B. Fischer, J. Rehm
Our article ‘Eyes Wide Shut’ – notably a group- and not
single-authored piece of work as seems to be implied by
both comments – evidently has triggered a strong reaction
from the commentators [1, 2]. Although we believe that
the evidence presented in the article and the commentar-
ies in large part speak for themselves, a couple of points
directly in response to the commentaries may be appro-
priate for clarification.
Our article was submitted in 2001, and took a very
long time to be reviewed and processed; thus, some of the
references cited by the commentaries were not available
at that time [3, 4].
Overall, our article was written as a critical conceptual
and empirical examination of methadone maintenance
treatment (MMT) – or a critically reflexive ‘devil’s advo-
cate’ piece, if you will. The objective was not to make an
argument or launch a campaign against MMT. Rather,
the intent was to critically examine the predominant
framing and rationale of the treatment, as well as the
nature and quality of the evidence used for broadly and
often categorically advocating MMT policy and practice.
This examination was in part triggered by the fact that
the field is overwhelmed by literature on MMT featuring
methodologically weak studies on treatment completers
only and on this skewed basis drawing positive conclu-
sions about MMT [5]. The other part is the increasing
diversity of opioid maintenance treatments. Given this
overall situation, the challenge is to find the optimal place
of MMT in a diverse landscape of alternative treatments.
Finding empirically based treatment matching and sys-
tem mixes is the challenge of the next years, and given the
rather sober experiences of controlled matching studies so
far, this will be a daring task to achieve [6, 7].
On the conceptual side, addiction – as well as treat-
ment – has always been heavily shaped by ideology and
morality politics. The fields of opioid dependence or
MMT have not been spared from those determinants
(which are socio-cultural constructs and not nature-giv-
en), and so they are worthwhile objects for reflexive exam-
ination [8, 9]. MMT may be for many constituents or
decision-makers a much more acceptable or desirable
intervention if it proves its potential for the reduction of
criminal victimization and social costs over individual
patient health and well-being. Again, the socio-political
context of treatment decisions does not directly influence
the effects of a substitution agent or intervention but may
provide critical explanations on why alternatives are cho-
sen or privileged.
Similarly, one key trigger for our article when first writ-
ten was the fact that although there are hundreds of MMT
studies, the vast majority are of problematic methodologi-
cal quality. MMT has been declared ‘effective’ and
pushed on the basis of evidence of a quality that would
not suffice for the establishment of a new treatment regi-
men in many other medical intervention fields [10]. Com-
parisons of MMT evidence after decades of research, as
exemplified by the recent Cochrane Review, compared to
reviews for other medications, are helpful in understand-
ing the real dynamics of adopting new medication, aside
from repetitions of evidence-based principles [3].
On this basis, we believe that the intentions of both our
author collective as well as the commentators aim at the
same goal: to provide the best possible interventions and
treatment for the very real problem of opioid dependence
or co-dependence. We also agree on the fact that currently
MMT plays an important role in this effort. We seem to
differ when it comes to defining this role in the mix of
modern intervention systems. In our view, having estab-
lished some efficacy or even effectiveness of one treat-
ment cannot and does not automatically determine its
role in social intervention systems, neither for methadone
nor for buprenorphine nor for heroin. Thus, rather than
reaffirming support for certain treatment regimes within
‘for-or-against’ paradigms, we should systematically and
empirically examine advantages and disadvantages of dif-
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ferent interventions in systems and ‘real life’ contexts,
including consumer or quality of life perspectives [11].
Finally, we should additionally keep in mind that in the
illicit drug field at the beginning of the 21st century, ideo-
logical and political pressures continue to be powerful
forces, often influencing or compromising strongest evi-
dence or best practice.
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